Host-Based Diagnostics for Acute Infections

The Capability Program Executive for Chemical, Biological, Radiological and Nuclear Defense (CPE CBRND) is issuing a Request for Information to identify scientifically mature, program‑ready candidates for the Advanced Differential Diagnostics (ADD) program. The goal is to develop host‑based assays that diagnose disease etiology, predict clinical outcomes, and guide therapeutic selection for warfighters exposed to CBRN threats. Desired products should be at Technology Readiness Level 4 or higher, use minimally invasive samples (e.g., peripheral or finger‑stick blood, respiratory specimens), and operate in low‑resource environments as a small, handheld or backpack‑sized device that is battery‑operable, functions in tropical humidity/temperature, and delivers results in ≤70 minutes (ideally ≤10 minutes) with ≥90 % clinical sensitivity and specificity. Additional requirements include a robust manufacturing and supply‑chain plan capable of rapid scale‑up, clear IP and data‑rights positions, and a cost estimate. Respondents must submit a three‑page white paper and a one‑page Quad Chart covering company profile and vision, corporate experience, teaming strategy, manufacturing capabilities, scalability, and any relevant clinical studies. The submission should also outline a high‑level development schedule, rough order‑of‑magnitude cost, and intellectual‑property considerations for commercial marketing. Responses are due by 22 May 2026, 15:00 EST, and should be emailed to usarmy.detrick.cpe‑cbrnd.mbx.baa army.mil with the appropriate subject line; questions may be directed to Keith Pereira (keith.d.pereira.civ army.mil). This RFI is for planning purposes only and does not constitute a solicitation or guarantee of future contract award.

Notice ID

5abb5c93153b4920b09fe802f9b45f6a

Solicitation Number

W911SR26RHDAI

NAICS Code

N/A

Classification Code

N/A